Open AccessUpregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus
Author(s) -
Nishio Eiji,
Hayashi Takanori,
Akaza Mao,
Hisatomi Yukiko,
Hikichi Masahiro,
Fujii Takuma,
Utsumi Toshiaki,
Harada Nobuhiro,
Shimono Yohei
Publication year - 2020
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12956
Subject(s) - downregulation and upregulation , everolimus , breast cancer , estrogen , medicine , cancer research , mcf 7 , oncology , cancer , biology , human breast , biochemistry , gene
Everolimus (EVE) is a drug that improves resistance to hormone therapy but may have adverse effects on EVE‐resistant patients. We indicated that even low concentrations of EVE could increase CIP2A expression in EVE‐resistant breast cancer cells. High CIP2A expression was associated with reduced luminal A breast cancer patient survival. Moreover, the expression of epithelial–mesenchymal transition‐related genes decreased in EVE‐resistant cells.